Adam Davidson, CEO of Trident Royalties, discusses offtake milestones and catalysts to boost FY24. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksNovacyt Regulatory News (NCYT)

Share Price Information for Novacyt (NCYT)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 66.20
Bid: 64.00
Ask: 66.60
Change: 0.00 (0.00%)
Spread: 2.60 (4.062%)
Open: 66.20
High: 0.00
Low: 0.00
Prev. Close: 66.20
NCYT Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Cancellation of trading of Yourgene Shares

11 Sep 2023 07:55

RNS Number : 9939L
Novacyt S.A.
11 September 2023
 

Novacyt S.A.

("Novacyt", the "Company" or the "Group")

 

De-listing and cancellation of trading of Yourgene Shares

 

Paris, France and Eastleigh, UK - 11 September 2023 - Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, notes today's announcement by Yourgene Health plc ("Yourgene"), in relation to the recommended cash offer made by Novacyt UK Holdings Limited ("Novacyt UK"), a wholly-owned subsidiary of Novacyt, for the entire issued and to be issued share capital of Yourgene announced on 3 July 2023 (the "Acquisition"), which is to be effected by means of a Court-sanctioned scheme of arrangement under Part 26 of the Companies Act 2006 (the "Scheme").

 

Further to the announcement made by Yourgene on 8 September 2023 that the Scheme has now become Effective in accordance with its terms, Yourgene has today announced that, following an application to the London Stock Exchange, the admission to trading on AIM of Yourgene Shares has been cancelled with effect from 7.00 a.m. today, 11 September 2023.

 

Yourgene's full announcement can be found here: https://polaris.brighterir.com/public/yourgenehealth/news/rns/story/wkjon2r

 

Contacts

 

Novacyt SA

+44 (0)23 8074 8830

James Wakefield, Non-Executive Chairman

James McCarthy, Acting Chief Executive Officer

Numis (Financial Adviser and Joint Broker to Novacyt and Financial Adviser to Novacyt UK)

+44 (0)20 7260 1000

Freddie Barnfield / Stuart Ord / Duncan Monteith / Jack McLaren

SP Angel Corporate Finance LLP (Nominated Adviser and Joint Broker to Novacyt)

+44 (0)20 3470 0470

 

Matthew Johnson / Charlie Bouverat (Corporate Finance)

Vadim Alexandre / Rob Rees (Corporate Broking)

Allegra Finance (French Listing Sponsor)

Rémi Durgetto / Yannick Petit

 +33 (1) 42 22 10 10 r.durgetto@allegrafinance.com / y.petit@allegrafinance.com

Walbrook PR (Financial PR & IR)

Stephanie Cuthbert / Anna Dunphy / Phillip Marriage

+44 (0)20 7933 8780

novacyt@walbrookpr.com

 

About Novacyt Group

Novacyt is an international diagnostics business delivering a broad portfolio of in vitro and molecular diagnostic tests for a wide range of infectious diseases, enabling faster, more accurate, accessible testing to improve healthcare outcomes. The Company provides customers with a seamless sample-to-result workflow using its integrated and scalable instrumentation/solutions. The Company specialises in the design, manufacture, and supply of real-time PCR kits, reagents and a full range of laboratory and qPCR instrumentation for molecular biology research and clinical use. Novacyt offers one of the world's most varied and comprehensive range of qPCR assays, covering human, veterinary, biodefence, environmental, agriculture and food testing.

 

Novacyt is headquartered in Vélizy in France with offices in Stokesley and Eastleigh, UK, and is listed on the London Stock Exchange's AIM market ("NCYT") and on the Paris Stock Exchange Euronext Growth ("ALNOV").

 

For more information, please refer to the website: www.novacyt.com

 

About Yourgene Health

Yourgene Health is an international integrated technologies and services business, enabling the delivery of genomic medicine. The Group works in partnership with global leaders in DNA technology to advance diagnostic science.

 

Yourgene primarily develops, manufactures, and commercialises simple and accurate molecular diagnostic and screening solutions, for reproductive health and precision medicine. The Group's portfolio of in vitro diagnostic products includes non-invasive prenatal tests (NIPT) for Down's Syndrome and other genetic disorders, Cystic Fibrosis screening tests, invasive rapid aneuploidy tests and DPYD genotyping assays.

 

Building on our expertise in genomic technology, Yourgene's Ranger® Technology offers next generation size selection with a range of sample preparation platforms for dynamic target enrichment. Ranger® Technology can be utilised to improve workflows and performance in multiple applications including NIPT, oncology, infectious disease testing and gene synthesis.

 

Yourgene Genomic Services offers a clinical service from UK and Taiwan focusing on precision medicine and reproductive health, including NIPT.

 

Yourgene Health is headquartered in Manchester, UK with offices in Taipei, Singapore, the US and Canada, and is listed on the London Stock Exchange's AIM market under the ticker "YGEN".

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCFIFLRADILLIV
Date   Source Headline
14th Jun 20192:45 pmRNSConversion of Loan Notes
3rd Jun 20192:00 pmRNSLiquidity Agreement and Total Voting Rights
24th May 20197:00 amRNSPublication of Annual Report and Notice of AGM
17th May 20194:35 pmRNSConversion of Loan Notes
15th May 20195:30 pmRNSConversion of Loan Notes
13th May 20197:00 amRNSLaunch of Next-Generation qPCR Instrument
3rd May 20196:23 pmRNSConversion of Loan Notes
3rd May 20197:00 amRNSChange of Adviser
1st May 20195:30 pmRNSLiquidity Agreement
30th Apr 20197:00 amRNSFull Year 2018 Results
25th Apr 20197:00 amRNSUpdate on Notice of Full Year Results
23rd Apr 20197:00 amRNSConvertible Bond Facility
8th Apr 20197:00 amRNSExpanded Development Partnership with Immunexpress
1st Apr 20192:30 pmRNSLiquidity Agreement and Total Voting Rights
4th Mar 20197:00 amRNSLiquidity Agreement and Total Voting Rights
26th Feb 20197:00 amRNSFunding Update
1st Feb 20192:00 pmRNSLiquidity Agreement and Total Voting Rights
22nd Jan 20197:00 amRNSRevenues Full Year 2018
2nd Jan 201912:30 pmRNSLiquidity Agreement and Total Voting Rights
24th Dec 20187:00 amRNSTrading Update
21st Dec 20187:00 amRNSNovacyt launches two new molecular diagnostic kits
11th Dec 20187:00 amRNSUpdate on Strategic Review
6th Dec 20187:00 amRNSCompletion of q16 molecular diagnostics order
3rd Dec 20181:00 pmRNSLiquidity Agreement and Total Voting Rights
30th Nov 201812:06 pmRNSReplacement: Unsecured Debt Facility
27th Nov 20187:00 amRNS$3.0M supply agreement with Genesis Diagnostics
1st Nov 20185:45 pmRNSLiquidity Agreement
1st Oct 201810:51 amRNSLiquidity Agreement and Total Voting Rights
26th Sep 20187:00 amRNSNovacyt Half Year 2018 Results
13th Sep 20187:00 amRNSNovacyt Partners with Applied Microarrays
3rd Sep 201811:15 amRNSLiquidity Agreement and Total Voting Rights
2nd Aug 201810:30 amRNSLiquidity Agreement and Total Voting Rights
2nd Aug 20187:00 amRNSHalf Year Revenue Update
26th Jul 20187:00 amRNSRevenue update to be announced on 2 August 2018
2nd Jul 201811:45 amRNSLiquidity Agreement Update and Total Voting Rights
28th Jun 20187:00 amRNSAcquisition of ID Business from Omega Diagnostics
12th Jun 201811:45 amRNSReplacement - Results of Annual General Meeting
12th Jun 20187:00 amRNSResults of Annual General Meeting
5th Jun 20187:00 amRNSLaunch of New Product in Infectious Mononucleosis
1st Jun 20183:30 pmRNSLiquidity Agreement and Total Voting Rights
30th May 20186:30 pmRNSNew Unsecured Debt Facility
23rd May 20182:51 pmRNSPublication of Annual Report and Notice of AGM
1st May 20184:30 pmRNSLiquidity Agreement Update and Total Voting Rights
26th Apr 20187:00 amRNSNovacyt Full Year 2017 Results
3rd Apr 20181:30 pmRNSLiquidity Agreement Update and Total Voting Rights
22nd Mar 20187:00 amRNSSigning of Assay Development Contract with GenePOC
1st Mar 20182:59 pmRNSLiquidity Agreement Update and Total Voting Rights
1st Feb 20183:15 pmRNSLiquidity Agreement Update and Total Voting Rights
26th Jan 20189:32 amRNSNotification of major holdings
24th Jan 20187:00 amRNSNOVACYT REVENUES FULL YEAR 2017

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.